Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

Autor: Tkachev, Alexander, Kalimullina, Dilara, Petryka, Robert, Osipenko, Marina, Tsarynna, Nataliia, Bilianskyi, Leonid, Kleczkowski, Dariusz, Yurkiv, Andrii, Woynarowski, Marek, Abrahamovych, Orest, Ivanishyn, Olha, Rydzewska, Grazyna, Kierkus, Jaroslaw, Petrova, Elina, Vasilevskaya, Olga, Afanasieva, Halyna, Francesconi, Carlos, Leszczyszyn, Jaroslaw, Bunkova, Elena, Platonov, Dmitry, Datsenko, Olena, Gridnyev, Oleksii, Hospodarsky, Ihor, Prystupa, Liudmyla, Stanislavchuk, Mykola, Pershko, Anatoly, Shchukina, Oksana, Simanenkov, Vladimir, Golovchenko, Oleksandr, Holderman, William, Lasa, Juan, Begun, Jakob, de Lourdes de Abreu Ferrari, Maria, Lopez, Pedro, Obrezan, Andrey, Farooq, Shiraz, Tiongco, Felix, Novillo, Abel, Tron, Emiliano, Macrae, Finlay, Leong, Rupert, Yukie Sassaki, Ligia, Zaltman, Cyrla, Kaiser Junior, Roberto, Stallmach, Andreas, Klaus, Jochen, Martinez, Manuel, Ruiz, Azalia, Abdulkhakov, Rustem, Sharma, Vishvinder, Korman, Louis, Lord, James, Patel, Bhaktasharan, Ritter, Timothy, Feagan, Brian G ^*, Sands, Bruce E, Sandborn, William J, Germinaro, Matthew, Vetter, Marion, Shao, Jie, Sheng, Shihong, Johanns, Jewel, Panés, Julián

Publikováno v: In The Lancet Gastroenterology & Hepatology April 2023 8(4):307-320